Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

ADMA Biologics, Inc.

ADMA ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$11.41

▼ -2.89%

Market Cap $2.56B · Vol 915.38K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

16.18

FWD: 13.01

Market Cap

$2.56B

Mid Cap

Div Yield

N/A

EPS Growth

+30.00%

YoY

RSI (14)

69.77

Momentum

Beta

0.67

vs Market

52W High

$20.43

44.15% below

52W Low

$7.22

58.03% above

Volume

915.38K

Avg 987.80K

P/B

9.09

Price-to-book

ROE

N/A

Return on equity

Free Float

97.03%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, ADMA Biologics, Inc. (ADMA) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ADMA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.84%

+13.76%

+31.60%

+11.32%

YTD

-37.45%

-25.28%

+237.57%

+784.50%

Financials & Valuation

TTM · Annual

Total Revenue	$510.17M
Net Income	$146.93M
Revenue Growth (YoY)	+1.98%
Gross Margin	57.36%
Operating Margin	37.53%
Net Profit Margin	28.80%
ROE	N/A
ROA · ROIC	32.82% · 31.45%

P/E Ratio	16.18
Forward P/E (FY1)	13.01
PEG Ratio	-1.16
P/S	8.76
P/B	9.09
P/FCF	162.41
EPS Growth	+30.00%
Outstanding Shares	223.98M

Technical Indicators

50-Day SMA	$10.00
200-Day SMA	$10.96
RSI (14)	69.77
Beta	0.67
52-Week High	$20.43
52-Week Low	$7.22

Volume Today	915.38K
Avg Daily Volume (30D)	987.80K
Relative Volume	0.93x
Volatility (10D)	38.95
Volatility (30D)	39.55
Free Float	97.03%

Analyst Consensus

BUY

Current Price $11.41

Mean Target $17.00

52W Low$7.22 52W High$20.43

Current

Target

$7.22 $20.43

Current Analyst target

+48.99% upside potential · 3 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG002NCK5N4

ISINUS0008991046

CountryUSA

Sub-IndustryBiopharmaceuticals

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

REGN Regeneron Pharmaceuticals, Inc. +13.33% CSL.AX CSL Limited +1.64% UCB.BR Ucb SA +0.50% 207940.KS SAMSUNG BIOLOGICS CO.,LTD. +8.86% BIIB Biogen Inc. +1.59%

Company Profile

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.